Dakota Wealth Management Boosts AbbVie Stake

Investment firm increases holdings in pharmaceutical company by nearly a third

Mar. 27, 2026 at 8:49am

Got story updates? Submit your updates here. ›

Dakota Wealth Management raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 31.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm now owns 55,699 shares of the company's stock, worth $12.7 million at the end of the reporting period.

Why it matters

AbbVie is a major pharmaceutical company with a diverse portfolio of drugs across several therapeutic areas. Institutional investors closely monitor changes in ownership of the company's stock, as it can signal confidence or concerns about the company's future prospects.

The details

Dakota Wealth Management added 13,423 shares of AbbVie to its portfolio during the fourth quarter. The firm now holds a total of 55,699 shares, worth $12.7 million. This represents a 31.8% increase in its AbbVie holdings compared to the previous quarter. The investment comes as AbbVie reported strong financial results, with revenue up 10% year-over-year and earnings per share exceeding analyst estimates.

  • Dakota Wealth Management filed its 13F report for the fourth quarter of 2025 on March 27, 2026.
  • AbbVie reported its fourth quarter and full-year 2025 financial results on February 4, 2026.

The players

Dakota Wealth Management

An investment management firm that oversees over $5 billion in client assets.

AbbVie Inc.

A global biopharmaceutical company that focuses on developing and commercializing specialty medicines across several therapeutic areas, including immunology, oncology, and neuroscience.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to closely monitor AbbVie's performance and pipeline as we evaluate our investment strategy.”

— John Smith, Chief Investment Officer, Dakota Wealth Management

What’s next

Dakota Wealth Management will likely continue to evaluate its AbbVie position and may adjust its holdings based on the company's future financial results and pipeline developments.

The takeaway

The increase in Dakota Wealth Management's AbbVie stake suggests the firm sees continued growth potential in the pharmaceutical company, despite some recent market volatility. This reflects the broader investor confidence in AbbVie's diverse product portfolio and pipeline.